A Phase 3 interventional study of UT-15C SR and treprostinil diethanolamine in Pulmonary Arterial Hypertension, sponsored by United Therapeutics. Completed at 1 site in United States. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-01-03.
Sponsored by United Therapeutics · Phase 3, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing treprostinil in Pulmonary Arterial Hypertension — 3 open to participants now, 5 under way, 2 of them phase 3. treprostinil · Pulmonary Arterial Hypertension.
Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, this one is the 34th largest by enrollment, is one of 2 that started in 2013, is one of 14 in phase 3, and was the 25th registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →3 of the 44 studies testing treprostinil in Pulmonary Arterial Hypertension are open now, in 1 country. Recruiting first, the newest first:
Liquidia Technologies, Inc. · Sites in United States
Ages 18–80
University of Arizona · Sites in United States
Ages 18+
Shanghai Zhongshan Hospital
Ages 18–75
By country, each count listing its studies:
treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 12 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2013.
This study's enrollment of 13 is below the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 32 across the 44 interventional studies. Of the 32 that completed or were terminated, 20 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 44 have an industry lead sponsor. The 10 most frequent:
United Therapeutics is the lead sponsor of 85 studies on the registry; 8 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
51 studies in Pulmonary Arterial Hypertension by United Therapeutics: 1 open now, 3 under way, 1 of them phase 3. Of 40 finished, 28 (70%) have results posted.
Among the 51 studies in Pulmonary Arterial Hypertension by United Therapeutics, this one is the 33rd largest by enrollment of the 45 interventional ones that give a count, is one of 5 that started in 2013, is one of 17 in phase 3, and was the 33rd registered.
United Therapeutics’s Pulmonary Arterial Hypertension studies by the year they started, since 2002.
1 of the studies testing treprostinil in Pulmonary Arterial Hypertension that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07759804Liquidia Technologies, Inc.A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, from their registry updates:
Among United Therapeutics’s 51 in Pulmonary Arterial Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A sub-study to the TDE-PH-304 protocol to assess the pharmacokinetics of patients transitioning from a twice daily dosing regimen of oral treprostinil to a three times daily dosing regimen.
As noted above in "Brief Summary".
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: UT-15C SR · Drug: treprostinil diethanolamine
Open label study drug.
Also known as: UT-15C Sustained Release (SR)
To Assess the Pharmacokinetics (Mean AM Dose) in Subjects During Twice Daily (BID) Dosing (up to 14 Days Prior to Transitioning to Three Times Daily [TID] Dosing Regimen at PK Visit 1) and up to 35 Days After Transitioning to TID Dosing (at PK Visit 2).
The PK sampling occurred over a 12-hour period in subjects during BID dosing (PK Visit 1) and during TID dosing (PK Visit 2). Prior to each PK sampling day, subjects must have been receiving a stable dose for at least 5 days.
Time frame: Up to 14 days prior to transitioning to TID dosing regimen (PK Visit 1) and up to 35 days after transitioning to TID dosing regiment (PK Visit 2)
To Assess the Pharmacokinetics (Cmax, Cmin) in Subjects During BID Dosing (up to 14 Days Prior to Transitioning to TID Dosing Regimen at PK Visit 1) and up to 35 Days After Transitioning to TID Dosing Regiment (PK Visit 2)
The PK sampling occurred over a 12-hour period in subjects during BID dosing (PK Visit 1) and during TID dosing (PK Visit 2). Prior to each PK sampling day, subjects must have been receiving a stable dose for at least 5 days.
Time frame: Up to 14 days prior to transitioning to TID dosing regimen (PK Visit 1) and up to 35 days after transitioning to TID dosing regiment (PK Visit 2)
To Assess the Pharmacokinetics (AUClast) in Subjects During Twice Daily (BID) Dosing (up to 14 Days Prior to Transitioning to Three Times Daily [TID] Dosing Regimen at PK Visit 1) and up to 35 Days After Transitioning to TID Dosing (at PK Visit 2).
The PK sampling occurred over a 12-hour period in subjects during BID dosing (PK Visit 1) and during TID dosing (PK Visit 2). Prior to each PK sampling day, subjects must have been receiving a stable dose for at least 5 days.
Time frame: 0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hours post-dose at up to 14 days prior to transitioning to TID dosing regimen (PK Visit 1) and at up to 35 days after transitioning to TID dosing regiment (PK Visit 2)
To Assess 6-minute Walk Distance for Both Groups (BID and TID) 3 to 6 Hours Post-morning Dose.
The 6-minute walk test (6MWT) was conducted at PK Visits 1 and 2, and was performed between hours 3 to 6 post-morning dose to correlate with the predicted peak plasma concentration of oral treprostinil.
Time frame: The 6MWT was conducted during BID dosing PK collection (up to 14 days prior to transitioning to TID dosing regimen [PK Visit 1]) and during TID dosing PK collection (up to 35 days after transitioning to TID dosing regimen [PK Visit 2]).
To Compare the Adverse Event (AE) Profile of BID Versus TID Dosing.
AE diaries including 8 therapy-specific terms were collected during both BID and TID dosing to allow for comparison of events from both regimens. The therapy-specific events included: diarrhea, extremity pain, flushing, headache, hypotension, jaw pain, nausea, and vomiting.
Time frame: The AEs were recorded for up to 50 days.
| Milestone | Open-label Extension PK Population |
|---|---|
| Started | 13 |
| Completed | 13 |
| Not completed | 0 |
The PK sampling occurred over a 12-hour period in subjects during BID dosing (PK Visit 1) and during TID dosing (PK Visit 2). Prior to each PK sampling day, subjects must have been receiving a stable dose for at least 5 days.
| mg | PK Visit 1 | PK Visit 2 |
|---|---|---|
| To Assess the Pharmacokinetics (Mean AM Dose) in Subjects During Twice Daily (BID) Dosing (up to 14 Days Prior to Transitioning to Three Times Daily [TID] Dosing Regimen at PK Visit 1) and up to 35 Days After Transitioning to TID Dosing (at PK Visit 2). | 8.12 (2.00 to 17.5) | 6.75 (1.25 to 15.0) |
The PK sampling occurred over a 12-hour period in subjects during BID dosing (PK Visit 1) and during TID dosing (PK Visit 2). Prior to each PK sampling day, subjects must have been receiving a stable dose for at least 5 days.
| ng/mL | PK Visit 1 | PK Visit 2 |
|---|---|---|
| Cmax | 8.60 (1.70 to 18.2) | 8.94 (2.25 to 16.8) |
| Cmin | 1.19 (0.290 to 2.50) | 2.14 (0.263 to 6.12) |
The PK sampling occurred over a 12-hour period in subjects during BID dosing (PK Visit 1) and during TID dosing (PK Visit 2). Prior to each PK sampling day, subjects must have been receiving a stable dose for at least 5 days.
| h*ng/mL | PK Visit 1 | PK Visit 2 |
|---|---|---|
| To Assess the Pharmacokinetics (AUClast) in Subjects During Twice Daily (BID) Dosing (up to 14 Days Prior to Transitioning to Three Times Daily [TID] Dosing Regimen at PK Visit 1) and up to 35 Days After Transitioning to TID Dosing (at PK Visit 2). | 47.8 (8.92 to 80.6) | 58.0 (10.8 to 109) |
The 6-minute walk test (6MWT) was conducted at PK Visits 1 and 2, and was performed between hours 3 to 6 post-morning dose to correlate with the predicted peak plasma concentration of oral treprostinil.
| Meters | PK Visit 1 | PK Visit 2 |
|---|---|---|
| To Assess 6-minute Walk Distance for Both Groups (BID and TID) 3 to 6 Hours Post-morning Dose. | 332.5 (177 to 525) | 347.9 (223 to 541) |
AE diaries including 8 therapy-specific terms were collected during both BID and TID dosing to allow for comparison of events from both regimens. The therapy-specific events included: diarrhea, extremity pain, flushing, headache, hypotension, jaw pain, nausea, and vomiting.
| percentage of subjects | PK Visit 1 | PK Visit 2 |
|---|---|---|
| Diarrhea | 46 | 38 |
| Extremity pain | 54 | 38 |
| Flushing | 85 | 54 |
| Headache | 69 | 85 |
| Hypotension | 23 | 23 |
| Jaw Pain | 38 | 46 |
| Nausea | 38 | 77 |
| Vomiting | 0 | 0 |
Collected over Approximately 50 days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PK Visit 1 | — | 0/13 (0%) | 13/13 (100%) |
| PK Visit 2 | — | 0/13 (0%) | 13/13 (100%) |
| Event | PK Visit 1 | PK Visit 2 |
|---|---|---|
| FlushingVascular disorders | 11/13 | 7/13 |
| HeadacheNervous system disorders | 9/13 | 11/13 |
| NauseaGastrointestinal disorders | 5/13 | 10/13 |
| Extremity painMusculoskeletal and connective tissue disorders | 7/13 | 5/13 |
| DiarrheaGastrointestinal disorders | 6/13 | 5/13 |
| Jaw painMusculoskeletal and connective tissue disorders | 5/13 | 6/13 |
| HypotensionVascular disorders | 3/13 | 3/13 |
| VomitingGastrointestinal disorders | 0/13 | 0/13 |
| Age, Categorical(Participants) | Open-label Extension PK Population |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 7 |
| >=65 years | 6 |
| Age, Continuous(years) | Open-label Extension PK Population |
|---|---|
| Mean | 60.6 (38 to 71) |
| Sex: Female, Male(Participants) | Open-label Extension PK Population |
|---|---|
| Female | 11 |
| Male | 2 |
| Ethnicity (NIH/OMB)(Participants) | Open-label Extension PK Population |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 13 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Open-label Extension PK Population |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 12 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Open-label Extension PK Population |
|---|---|
| United States | 13 |
The record gives a start of Aug 2013, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2016, 2 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Treprostinil
Pulmonary Arterial Hypertension →